In a study using a NAFLD mouse model and an AML-12 cell line, rhein treatment was shown to decrease triglyceride (TG) levels in AML-12 cells and reduce serum levels of TG, total cholesterol (TC), malondialdehyde (MDA), alanine transaminase (ALT), aspartate transaminase (AST), and non-esterified fatty acids in the mice. This evidence concerns the gene GPT and metabolic dysfunction-associated steatotic liver disease.